Experimental cell therapy targets tough leukemia in small early trial
NCT ID NCT07491263
First seen Mar 30, 2026 · Last updated May 06, 2026 · Updated 6 times
Summary
This early-phase study tests a new treatment called QH103 for people with a type of leukemia (B-ALL) that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-γδ T cells) designed to find and attack cancer cells. The main goal is to check safety and find the right dose in just 6 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CD19-POSITIVE B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of fujian medical university
Fuzhou, Fujian, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.